---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-013776"
form_type: "8-K"
ticker: "COCP"
cik: "0001412486"
company_name: "Cocrystal Pharma, Inc."
filed_at: "2025-06-05T23:59:59+00:00"
generated_at: "2026-05-19T21:41:05.358185+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Cocrystal Pharma's norovirus antiviral CDI-988 to be presented at MHSRS in August 2025

## Summary
- CDI-988, a broad-spectrum protease inhibitor, will be featured in an oral presentation at the 2025 Military Health System Research Symposium on August 4, 2025 in Kissimmee, Florida.
- Cocrystal is developing CDI-988 as a norovirus prophylaxis and treatment; no approved antivirals or vaccines for norovirus currently exist.
- President and co-CEO Sam Lee, PhD, will discuss Phase 1 safety, tolerability, and pharmacokinetics results at the conference.
- CDI-988 targets a highly conserved region in 3CL viral proteases, potentially halting infection early regardless of viral strain or mutation.
- Norovirus spreads rapidly in confined spaces like military settings, posing a threat to operational effectiveness and economic burden.

## SEC filing metadata
- accession: 0001641172-25-013776
- form_type: 8-K
- ticker: COCP
- cik: 0001412486
- company_name: Cocrystal Pharma, Inc.
- filed_at: 2025-06-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1412486/000164117225013776/0001641172-25-013776-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1412486/000164117225013776/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-013776
- JSON: https://secwatch.observer/filing/0001641172-25-013776.json
- Plain text: https://secwatch.observer/filing/0001641172-25-013776.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.